Table 1.
Clinicobiological characteristics of ALK-rearranged NSCLC patients.
| Patient | Treatment | Age at baseline (y/o) | Sex | Smoking status (PY) | Numbers of metastatic sites at baseline | ECOG PS at baseline | Number of previous treatment lines | Number of previous treatment lines with prior ALK inhibitor | Duration of treatment (months) | Progression-free survival (months) | Count of CTCs by CellSearch at PD (/7.5 mL) | Count of CTCs by FACS at PD (/20 mL) | Biopsy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P43 | Crizotinib | 68 | F | 0 | 2 | 1 | 0 | 0 | 4.7 | 4.7 | 0 | 15 | No |
| P46 | Crizotinib | 29 | M | 5 | 3 | 0 | 0 | 0 | 13.7 | 13.7 | 0 | 12 | No |
| P49 | Crizotinib | 59 | F | 20–25 | 3 | 1 | 3 | 0 | 3.6 | 3.6 | 13 | 24 | No |
| P50 | Crizotinib | 69 | M | 40 | 2 | 2 | 1 | 0 | 9.9 | 9.3 | 7 | 10 | No |
| P41 | Lorlatinib | 42 | M | 0 | 2 | 0 | 3 | 2 | 13.5 | 13.3 | 0 | 10 | No |
| P45 | Lorlatinib | 59 | F | 0 | 4 | 2 | 3 | 3 | 4.1 | 3.6 | 2 | 11 | Post-progression |
ECOG Eastern Cooperative Oncology Group, PS performance status, PY pack-year, y/o years old, PD progression disease.